Opinion|Videos|January 10, 2025
Understanding the CAR-T Treatment Process
Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient evaluation and selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which patients do you think about consider for CAR-T in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR-T referral?
- How do non-medical factors (location, money, etc) impact patient selection?
- Walk us through the typical CAR-T referral process at your institution, - from the initial community physician outreach to the patient evaluation and selection.
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5